Nadolol block of Nav1.5 does not explain its efficacy in the long QT syndrome

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 3, 2012, Pages 249-253

  Besana, Alessandra ^a   Wang, Dao W ^b   George Jr , Alfred L ^c   Schwartz, Peter J ^d,e,f,g  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b NANJING MEDICAL UNIVERSITY   (China)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

blockers; long QT syndrome; nadolol; sodium channel blockers

Indexed keywords

METOPROLOL; NADOLOL; PROPRANOLOL; SODIUM CHANNEL NAV1.5;

ARTICLE; BIOPHYSICS; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; LONG QT SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SODIUM CURRENT; STEADY STATE; WHOLE CELL;

ADRENERGIC BETA-ANTAGONISTS; CELL LINE; HUMANS; LONG QT SYNDROME; METOPROLOL; MUTATION; NADOLOL; PATCH-CLAMP TECHNIQUES; PROPRANOLOL; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 84858793802     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823d2fd1     Document Type: Article

References (15)

1. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120:1761-1767.
2. Schwartz PJ, Crotti L. Long QT and short QT syndromes. In: Zipes DP and Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 5th ed. Philadelphia, PA: Elsevier/Saunders; 2009:731-744.
3. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long QT syndrome. Gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89-95. (Pubitemid 32050441)
4. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381-3386.
5. Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975;89:378-390.
6. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J. 1985;109:399-411. (Pubitemid 16248481)
7. Schwartz PJ, Crotti L, Insolia R. Long QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. In press.
8. Chatrath R, Bell CM, Ackerman MJ. b-Blocker therapy failures in symptomatic probands with genotyped long-QT syndrome. Pediatr Cardiol. 2004;25:459-465. (Pubitemid 39382810)
9. Wang DW, Mistry AM, Kahlig KM, et al. Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front. Pharmacol. 2010;1:144.
10. Bankston JR, Kass RS. Molecular determinants of local anesthetic action of b-blocking drugs: implications for therapeutic management of long QT syndrome variant 3. J Mol Cell Cardiol. 2010;48:246-253.
11. Bennett PB, Yazawa K, Makita N, et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376:683-685.
12. + channel-linked long-QT syndrome. Circ Res. 1996;78:916-924. (Pubitemid 26131376)
13. Wang DW, Crotti L, Shimizu W, et al. Malignant perinatal variant of long QT syndrome caused by a profoundly dysfunctional cardiac sodium channel. Circ Arrhythm Electrophysiol. 2008;1:370-378.
14. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007;115:2481-2489. (Pubitemid 46763221)
15. Crotti L, Spazzolini C, Schwartz PJ, et al. The common long QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366-2375. (Pubitemid 350145071)